IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bruno Simoneau et al) Art Unit: 1614

U.S. Appln. No. : 10/719,369) Examiner: To be assigned

Confirmation No.: 3601

U.S. Filing Date: November 21, 2003

Title of Invention: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Attny. Docket No.: 13/116

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

July 23, 2004

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT
Sir:
Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.
1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

The fee set forth in 37 C.F.R. §1.17(p).

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a terpart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or
	foreign makin inform §1.56(No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after g reasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 C.F.R. (c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
ounte n sect	rpart ap ion 1.56	d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated of (c) more than thirty (30) days prior to the filing of the accompanying inclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4868 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on July 23, 2004.

Alan R. Stempel, Reg. No. 28,

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reu-Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUL 2 7 2004

Application Number 10/719,369 Filing Date November 21, 2003 First Named Inventor Bruno Simoneau Art Unit 1614 **Examiner Name** To be assigned

13/116

(Use as many sheets as necessary) Attorney Docket Number 2

U. S. PATENT DOCUMENTS Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where							
Initials*	No.1	Number-Kind Code ^{2 (Il known)}	- MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		^{US-} 6,124,307	09/26/2000	Rakesh Vig et al			
		US-					
	***************************************	US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
·····	***************************************	US-					
		US-					
		ŪS-	* 1				
	***************************************	US-	***				
······································		US-		***************************************			
***************************************	· ·····	US-					
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS						
Examiner	Cite No. ¹	Foreign Patent Document	Publication Date	Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			T ⁶
	<u> </u>	WO 02/070470 A2	09/12/2002	Smithkline Beecham	-	
		WO 02/32889 A1	04/25/2002	Parker Hughes Inst.	***************************************	
	Ī	WO 99/55676	11/04/1999	Centre National De La Recherche Scientifique	***************************************	
	1	WO 00/03998	01/27/2000	Novirio Pharmaceuticals Limited	***************************************	

Examiner	Date	
Signature		sidered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUL 2 7 2004

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

2

Complete if Known				
Application Number	10/719,369			
Filing Date	November 21, 2003			
First Named Inventor	Bruno Simoneau			
Art Unit	1614			
Examiner Name	To be assigned			
Attorney Docket Number	13/116			

NON PATENT LITERATURE DOCUMENTS					
Examiner nitials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		IRENE M. LAGOJA ET AL; 1,2,4-Triazole Derivatives Inhibiting the Human Immunodeficiency Virus Type 1 (HIV-1) in vitro; Helvetica Chimica Acta (2002) Vol 85 No. 7 pages 1883-1892; Rega Institute for Midical Research			
		International Search Report Reference Number PCT/CA 03/01870			

			ļ		

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.